• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa

The new treatment for this extremely neglected disease is safer and reduces the number of toxic daily injections and hospitalization time.

Home > Press releases

Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa

The new treatment for this extremely neglected disease is safer and reduces the number of toxic daily injections and hospitalization time.

Lab Activities
Nairobi, Kenya — 29 Sep 2022
  • English
    • English
    • አማርኛ
    • العَرَبِية
    • Português
    • Español

A shorter, and less toxic treatment for people with visceral leishmaniasis was shown to be effective thanks to a study conducted in Eastern Africa by the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) and its partners. The results were published in The Clinical Infectious Diseases journal.

The new treatment consists of a combination of two drugs: miltefosine (MF), the only oral drug available for leishmaniasis treatment, and paromomycin (PM), an injectable antibiotic.

‘This new treatment is great news for the thousands of patients affected by visceral leishmaniasis in the region. It will eliminate one painful and toxic injection from the treatment and is therefore safer for those affected,’ said Prof. Ahmed Musa, Deputy Vice Chancellor at the University of Khartoum and Principal Investigator of the clinical trial conducted in Sudan.

Leishmaniasis is the deadliest parasitic killer after malaria. Its most severe form, visceral leishmaniasis, is fatal if left untreated. There are 50,000 to 90,000 new cases of the disease annually, with the highest number of cases worldwide reported in Eastern African countries: Eritrea, Ethiopia, Kenya, Somalia, South Sudan, Sudan, and Uganda. The disease affects people in resource-limited settings, arid and semi-arid areas. Half of them are children under 15. Leishmaniasis is also a climate-sensitive disease, and its impact could get worse. Therefore, if not addressed, the most vulnerable will continue to suffer.  

The current first-line treatment in Eastern Africa consists of paromomycin (PM), an injectable antibiotic used in combination with sodium stibogluconate (SSG), administered either through injection or intravenously. It remains sub-optimal, as patients may suffer from rare but heavy side effects, such as cardiotoxicity, hepatotoxicity, and pancreatitis associated with SSG. The treatment is also difficult to administer since patients must endure two painful injections every day for 17 days.  

‘The current treatment has significant socio-economic impact as patients are forced to stay in hospital for extended periods and have to miss work or school. With the new treatment patients will spend less time in hospital,’ said Prof. Musa.  

The results announced today stem from a clinical trial initiated in 2017 in Kenya, Ethiopia, Sudan, and Uganda by the AfriKADIA Consortium with funding from The European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union; UK aid; the Dutch Ministry of Foreign Affairs (DGIS); the Federal Ministry of Education and Research (BMBF) through KfW, Germany; the Swiss Agency for Development and Cooperation (SDC); Médecins Sans Frontières; Medicor Foundation; and other private individuals and foundations. The study compared a new combination of two drugs, miltefosine and paromomycin, given for 14 days, to the standard of care of sodium stibogluconate and paromomycin given for 17 days.  

Results show that the MF+PM treatment is over 91% effective in treating visceral leishmaniasis. While this treatment is just as effective as the existing treatment, it has the advantage of reducing hospitalization time by 18% and removing one painful daily injection and the potential life-threatening toxicity associated with sodium stibogluconate. It is therefore more patient-friendly. Children, who are the majority of visceral leishmaniasis patients – were also shown to respond very well to this new treatment and will particularly benefit from it.  

The treatment also lowers the risk of the occurrence of post-kala-azar dermal leishmaniasis (PKDL) – a common complication of visceral leishmaniasis that appears after treatment mainly in Sudan and Ethiopia – to 4 %, lower than 20.9% if treated by SSG+PM. This is important because PKDL patients are a source of infection to sandflies, therefore reducing cases of PKDL will reduce transmission.    

‘The new combination treatment signifies a historical step forward for dreadfully neglected patient populations. After many decades we have finally included an oral treatment to the regimen, reducing severe side effects and the burden on health systems thanks to decreased hospitalization time,’ said Dr Monique Wasunna, DNDi Eastern Africa Regional Director in Nairobi, Kenya. 

Efforts have begun to share the study results with stakeholders in the region to facilitate the adoption of the new combination, so that patients can access the treatment soon.  

‘We are delighted with the positive results from this clinical trial. It will contribute to our strategic goal of reducing morbidity due to leishmaniasis by 60% by 2025,’ said Dr Patrick Amoth, Director General for Health at the Ministry of Health, Kenya. ‘I have asked my Technical Advisory Group to review the evidence provided by DNDi and make recommendations on the adoption of the new treatment.’ 

DNDi and its partners are working towards finding even better treatments that would completely remove the need for injectables and would be better adapted to local conditions. 

‘The journey is not over yet. DNDi and its partners will be beginning clinical trials for new, promising, all-oral treatments for leishmaniasis soon,’ said Dr Fabiana Alves, Director of Neglected Tropical Diseases leishmaniasis and mycetoma Cluster at DNDi. ‘Our goal is to radically transform treatments for visceral leishmaniasis by developing patient-friendly oral therapies that are affordable, safe, and effective in patients in all regions.’ 

The Science Explained

Cover page of The Science Explained: Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa

Evaluating an alternative treatment regimen for visceral leishmaniasis in Eastern Africa

About the AfriKADIA Consortium 

AfriKADIA is a consortium created to find improved treatments and diagnostic tools for visceral leishmaniasis in eastern Africa. Over the past 12 years, AfriKADIA Consortium partners have conducted innovative visceral leishmaniasis trials in the eastern Africa region. Many of these were joint efforts. The consortium comprises three leading universities and one research institution from eastern Africa as well as four leading European research institutions with a strong track record in field-based research and two well-respected not-for-profit product development partnerships specialised in R&D for neglected diseases.  

The AfriKADIA Consortium is funded by the European & Developing Countries Clinical Trials Partnership (EDCTP). This project is part of the EDCTP2 programme which is supported by the European Union under Horizon 2020, its Framework Programme for Research and Innovation. 

About DNDi

A not-for-profit research and development organization, DNDi  works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. DNDi is also coordinating the ANTICOV clinical trial to find treatments for mild-to-moderate COVID-19 cases in low-resource settings. Since its inception in 2003, DNDi  has delivered twelve new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness.  dndi.org  

Media contact

media@dndi.org

Linet Otieno (DNDi, Nairobi) 
latieno@dndi.org 
+254 705 639 909 

Ilan Moss (DNDi, New York)  
imoss@dndi.org   
+1 646 266 5216 

Photo credit: Sydelle Willow Smith – EDCTP

Clinical trials Visceral leishmaniasis

Read, watch, share

Loading...
Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License